SecBot SecBot
PRESS-RELEASE ·Filed Jul 9, 2026

MESO

Mesoblast Limited
MIXED
Impact 6/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The large EPS miss on a minimal base is a mechanical artifact and not a reflection of business deterioration, the key driver is commercial execution on Ryoncil. Watch for continued revenue growth updates from major U.S. pediatric centers. The cross-filing activist context amplifies pressure, making any positive revenue updates more impactful.

DirectionMixed
Confidencemedium
Horizonweeks

Drugs in focus

MESO drug pipeline →

rexlemestrocel-L

▲ Bullish Named in this press release
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.44
T+0 close · Jul 9, 2026 · via day close
Latest settled
−7.90%
T+60 · $14.22
Vs SPY
−10.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $15.44entry
  2. T+1 · 4mo ago +5.05%α +5.82% · $16.22
  3. T+5 · 4mo ago +15.67%α +16.23% · $17.86
  4. T+20 · 3mo ago +3.24%α +0.81% · $15.94
  5. T+60 · 6w ago −7.90%α −10.53% · $14.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast reported Q1 FY2026 EPS of -$0.07, missing consensus of -$0.03 by 133%. However, the company announced full-year Ryoncil net revenue of $115M, exceeding initial projections, with continued growth expected. The EPS miss is on a tiny base and the Ryoncil revenue narrative is the dominant driver, making the overall tone mixed.

Key Financial Metrics

EPS
−$0.07
est −$0.03 · -133.3%
Rating
miss

Key Facts

  • FY2026 Q1 EPS: -$0.07, -133% miss vs consensus -$0.03.
  • Ryoncil net revenue of US$36M for Q1 FY2026 and US$115M for full year ended June 30, 2026.
  • CEO stated revenue exceeded initial projections and anticipates continued growth.

Financial Impact

Revenue of $115M for FY2026, exceeding projections; EPS of -$0.07 vs -$0.03 estimate.

revenueeps

Risk Factors

  • Ryoncil revenue growth may not sustain the initial launch momentum.
  • Reliance on a single product for near-term revenue.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3325284

Track record

25 reports on MESO

Performance horizon

7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026